SignatureFD’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,478
| Closed | -$49.9K | – | 3573 |
|
|
2026
Q1 | $49.9K | Buy |
2,478
+895
| +57% | +$14.4K | ﹤0.01% | 1724 |
|
|
2025
Q4 | $25.6K | Sell |
1,583
-649
| -29% | -$8.6K | ﹤0.01% | 2005 |
|
|
2025
Q3 | $27.2K | Buy |
2,232
+840
| +60% | +$11.6K | ﹤0.01% | 1969 |
|
|
2025
Q2 | $15.7K | Buy |
1,392
+1,124
| +419% | +$13.7K | ﹤0.01% | 2163 |
|
|
2025
Q1 | $3.09K | Buy |
268
+187
| +231% | +$1.91K | ﹤0.01% | 2752 |
|
|
2024
Q4 | $686 | Sell |
81
-242
| -75% | -$2.51K | ﹤0.01% | 3098 |
|
|
2024
Q3 | $3.74K | Sell |
323
-27
| -8% | -$340 | ﹤0.01% | 2654 |
|
|
2024
Q2 | $4.12K | Buy |
350
+152
| +77% | +$1.77K | ﹤0.01% | 2576 |
|
|
2024
Q1 | $2.35K | Hold |
198
| – | – | ﹤0.01% | 2761 |
|
|
2023
Q4 | $2.43K | Buy |
198
+117
| +144% | +$1.06K | ﹤0.01% | 2715 |
|
|
2023
Q3 | $780 | Sell |
81
-7
| -8% | -$72 | ﹤0.01% | 2966 |
|
|
2023
Q2 | $792 | Buy |
+88
| New | +$811 | ﹤0.01% | 3015 |
|
|
2022
Q4 | – | Sell |
-548
| Closed | -$8K | – | 3348 |
|
|
2022
Q3 | $8K | Buy |
+548
| New | +$7.66K | ﹤0.01% | 2188 |
|
Other funds holding KALV
SignatureFD's KALV Position: Q2 2026 in Review
SignatureFD sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,478 shares — an estimated $49.9K sold.
SignatureFD first reported a position in KALV in Q3 2022 and held it in 13 quarters. The position peaked at $49.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- SignatureFD reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SignatureFD sold 2,478 KalVista Pharmaceuticals shares in Q2 2026, an estimated $49.9K.
- SignatureFD first reported a position in KalVista Pharmaceuticals in Q3 2022 and held it in 13 quarters.
- SignatureFD's KalVista Pharmaceuticals position peaked at $49.9K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.